Executive Summary Our "Basic Platform Report: Vascular Targeting Agents" provides a complete and systematic description of the past, present and future efforts in cancer R&D focused on the vascular targeting field. In only a few years time the number of candidates has been doubled, expanding from a handful of drugs to more than twenty. Several of who has entered clinical evaluation. The earlier and most talked candidates still remain at the top. However, the list of emerging competitors is growing and at least seven new VTAs have recently entered clinic settings. The close relation between vascular targeting and anti-angiogenesis also make it possible for new competitors to enter the scene in near future. A major competitor, with a strong anti-angiogenesis antibody portfolio, has already announced to hold a vascular targeting antibody in early stage of development.
BioSeeker Group has identified structured and defined information necessary to analyze the most important drugs currently under development. More than 25 drugs are included in this extensive guide. The report is divided in 6 sections each section structured to enable the study of a specific topic (see below). "Basic Platform Report: Vascular Targeting Agents" is a unique gathering of information found no were else. The information structure will provide an easy reading format to track B2B collaborations and industry academic relationships as well as identify drugs receiving Fast Track Designations and Orphan Drug Status. Example of drugs covered in the report 3G4, ABT-751, AVE8062A, AZD4440, BCH-19746, BCH-23541, CA4P, DMXAA, E4G10, EndoTAG-1, EndoTAG-2, Exherin, ILX-651, MLN2704, MLN591, MLN591RL, MN-029, MX116407, NPI-2358, OXi4503, OXi6197, OXi8009, Tarvacin, TZT-1027, VEGF121/rGel and ZD6126 etc. Example of companies included Peregrine Pharmaceuticals Inc., Abbot Laboratories, AstraZeneca, Oxigene, Antisoma, MediGene AG, Adherex Technologies Inc., ILEX Oncology Inc., Millenium Pharmaceuticals, Nereus Pharmaceuticals and Maxim Pharmaceuticals etc. The report will assist you in - Tracking cutting edge companies, therapies and new technologies
- Rapid identification of promising drug candidates and future partners & competitors
- Rapid identification of in-licensing opportunities
- Laying down a comprehensive framework for further analysis of the vascular targeting field
- Producing presentations surrounding the development of cancer therapeutics
- Identifying novel vascular targeting agents
Table of Contents Section I: Investigators This section will enable our customers to rapidly study and identify which investigators are active in vascular targeting R&D. It will as well assist in studying and build up a complete picture of research activities among the different investigators that are active in this field. Both industry and academic activities are included which facilitates the study of industry-industry as well as industry-academic collaborations. Section II: Drug candidates This section will assist in studying R&D activities and progress for the different drugs included. It will as well enable a historical description the progress of each drug and structure all collaborative partners involved in R&D for each drug candidate. Section II gives you a possibility to study activities and efforts for each drug in relation to different cancer indications. Section III: Developmental stage This section enables you to structure and study the level and progress that each drug candidate has reached. The time frame for a drug to progress from the different developmental phases (pre-clinical up to approved) reflects difficulties and commitment among the investigators. It as well provides the structure to analyze both a macro and micro perspective. Section IV: Therapeutic types This section enables you to track down competition among the different therapeutic types under development. Most types of therapeutic strategies have been defined and structured (small molecular drugs, monoclonal antibodies, improved antibodies, biological drugs, gene therapy, cell therapy, vaccines). It also provides the structure to analyze both a macro and micro perspective. Section V: Indications This section structures different diseases defined by BioSeeker Group. All major cancer indications are defined (brain, breast, colon, cervical, head & neck, leukemia, lymphoma, liver, lung, melanoma, myeloma, ovarian, prostate and renal cancers). Further more, each cancer indication is divided in sub-indication categories such as: NSCLC, SCLC, Androgen-Independent, Androgen-dependent, Hormone-Refractory, ALL, AML, CLL, CML, NHL, Stage 1-4, Relapsed, recurrent and metastatic cancers. This section assists our customers to study competitors and possible collaborative partners working in the same disease areas. It as well provides the structure to analyze both a macro and micro perspective. Section VI: Mechanism of action & Targets In this section BioSeeker Group provide an extensive defined structure over mechanisms and targets for the different drug candidates. It is divided in two categories, one general and one more specific.
General definitions: Androgen Antagonists, Cell-cycle inhibitors, Cell death pathway interactions, Cytokine effects, DNA intercalators, Cellular metabolism disruptions, Hormone agonists, Immunostimulations, MDR, Metalloproteinase inhibitors, Peptide hormones, Protein Kinase Inhibitors, Retinoids and Tumor Antigens.
Examples of specific molecular targets: VEGF/VEGFr, EGF/EGFr, microtubules, PKC, Proteasome inhibitor, MAP kinase, Histone deacetylase, DNA methyltransferase inhibitor, Farnesyl transferase (Ftase), Endothelin ET-A antagonist, CD20 etc.
|
